Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

A real-time and continuous brain monitoring system to record and track brain activity and extract biomarkers for neurological conditions

NS System

Neurological disorders, ranging from epilepsy, autism, dementias, Alzheimer’s and Parkinson’s diseases affect 1B people worldwide. Currently, Europe has the greatest percentage of population aged 65 or over (25%) and these numbers are expected to drastically grow (3% per year) increasing the population affected by brain disorders. Many neurological...
Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Altered mRNA translation as a pathogenic mechanism across neurodegenerative diseases

TRANSNEURO

Neurodegenerative and neurodevelopmental diseases constitute a major health burden, and in spite of several decades of intensive research, the molecular mechanisms underlying these diseases are still poorly understood, and effective drug treatments are generally lacking. Alterations in protein synthesis have been implicated in several of these...
Funding Programme
Start Date
End Date
Total Funding
€ 1 830 000
European Countries Involved

Biomarkers for Alzheimer’s disease and Parkinson’s disease.

BIOMARKAPD

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Funding Programme
Start Date
End Date
Total Funding
€ 449 066

BrainQ, non-invasive, very low intensity, BCI-based frequency dependent electromagnetic field tailored treatment for neuro recovery (BQ).

BQ-Technology

The WHO has identified neurological disorders as a major burden and emerging challenge to global healthcare systems. These range from causes such as stroke and dementia, to injuries and viral infections. The prevalence of strokes and dementia are strongly linked to increasing age, for example stroke risk more than doubles every decade after 55...
Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Can immune system rejuvenation restore age-related memory loss?

IMMUNE/MEMORY AGING

With increased life expectancy, there has been a critical growth in the portion of the population that suffers from age-related cognitive decline and dementia. Attempts are therefore being made to find ways to slow brain-aging processes; successful therapies would have a significant impact on the quality of life of individuals, and decrease...
Funding Programme
Start Date
End Date
Total Funding
€ 1 650 000
European Countries Involved

Deciphering ubiquitin-dependent regulation of Golgi homeostasis control in neurodegeneration

UbiGolD

Alzheimer’s disease (AD) is the most common neurodegenerative disorder which affects 47 million patients worldwide. However, the underlying molecular mechanisms leading to sporadic-AD remain unknown and preventive treatment is not yet available. Lately, the ubiquitin-proteasome system has been implicated in AD. Dr. Merbl’s laboratory recently...
Funding Programme
Start Date
End Date
Total Funding
€ 185 464
European Countries Involved

Dementia Ambient Care: Multi-Sensing Monitoring for Intelligent Remote Management and Decision Support

Dem@Care

The increase in average lifespan across the world has been accompanied by an unprecedented upsurge in the occurrence of dementia with high socio-economic costs. The development of personal health systems provides a means of dealing with such problems in a meaningful and sustainable manner, enabling persons with dementia to maintain independence and...
Funding Programme
Start Date
End Date
Total Funding
€ 10 626 393
European Countries Involved

Discovery of drugs for the treatment and prevention of Alzheimer's disease

ALZHEIMERSDRUG

Alzheimer’s disease is a neurodegenerative disease characterized by the accumulation of proteins and protein fragments in the brain, progressive neuronal loss, inflammation, and the gradual and inevitable decline of memory and cognition. Decline of memory and cognition is coupled with binding of β amyloid peptides (Aβ) and their derived diffusible...
Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved

Functional and synaptic deficits in cerebral cortical neurons in Alzheimer’s Disease model mice

AD SYNAPTIC DEFICITS

Alzheimer’s disease (AD) is the most common neurodegenerative disease, affecting millions of people worldwide and therefore it is fundamental to understand its underlying mechanisms. Although the neuropathologies involved in AD are well-described, the effect of those pathologies on neuronal function are poorly understood. Using a transgenic mouse...
Funding Programme
Start Date
End Date
Total Funding
€ 45 000
European Countries Involved

Generalised EMF Research using Novel Methods – an integrated approach: from research to risk assessment and support to risk management

GERONIMO

The EU population is increasingly exposed to new physical and chemical agents in the environment, some of which may be detrimental to public health. Of these, electromagnetic fields (EMF) are one of the most ubiquitous, with new EMF technologies and novel applications being actively developed and commercialised. To address pertinent questions on...
Funding Programme
Start Date
End Date
Total Funding
€ 7 853 407

GSK-3 in neuronal plasticity and neurodegeneration: basic mechanisms and pre-clinical assessment

NEURO.GSK3

Neuronal circuits in mammalian brain act predominantly via excitatory synapses on dendritic spines. Formation of new spines in adult brain constitutes the structural basis of neuronal plasticity. The underlying molecular mechanisms remain largely unknown but depend essentially on kinase-dependent signalling pathways. Final formation of synapses on...

Funding Programme
Start Date
End Date
Total Funding
€ 5 082 027
European Countries Involved

Identification of the process by which patients recall and UPDATE their subjective RISK assessments for various diseases to incorporate objective genetic risk information

RISK-UPDATE

Project RISK-UPDATE will support the reintegration of Dr Talya Miron-Shatz, after four years spent as post-doctoral research collaborator with Nobel Laureate Prof. Daniel Kahneman at Princeton University, in the USA. Dr Miron-Shatz’s new host institution is Ono Academic College, Israel, which has agreed to set up a new research centre to facilitate...
Funding Programme
Start Date
End Date
Total Funding
€ 100 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).